Is GENPF or JNJ a better dividend investment in 2026?

GENPF currently yields 14184.40% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: GENPF offers higher current income.

What is the dividend yield difference between GENPF and JNJ?

GENPF has a forward dividend yield of 14184.40% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 14182.27 percentage points.

Home › Compare › GENPF vs JNJ

GENPF vs JNJ: Dividend Comparison 2026

GENPF yields 14184.40% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 GENPF wins by $1741245461664930048.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

GENPF

● Live price

14184.40%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1741245461664930048.00M

Annual income

$1,717,427,461,345,424,000,000,000.00

Full GENPF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — GENPF vs JNJ

📍 GENPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	GENPF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, GENPF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

GENPF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GENPF

Annual income on $10K today (after 15% tax)

$1,205,673.76/yr

After 10yr DRIP, annual income (after tax)

$1,459,813,342,143,610,500,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, GENPF beats the other by $1,459,813,342,143,610,500,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GENPF + JNJ for your $10,000?

GENPF: 50%JNJ: 50%

100% JNJ50/50100% GENPF

Portfolio after 10yr

$870622730832465024.00M

Annual income

$858,713,730,672,712,000,000,000.00/yr

Blended yield

98.63%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GENPF

No analyst data

Altman Z

-559.1

Piotroski

1/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GENPF buys

JNJ buys

No recent congressional trades found for GENPF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricGENPFJNJ

Forward yield	14184.40% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$1741245461664930048.00M ✓	$30.3K
Annual income after 10y	$1,717,427,461,345,424,000,000,000.00 ✓	$4,689.40
Total dividends collected	$1739668430966621440.00M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: GENPF vs JNJ ($10,000, DRIP)

Year	GENPF Portfolio	GENPF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$1,429,140	$1,418,439.72	$10,592	$272.30	+$1.42M → GENPF
2	$190,982,313	$189,453,134.00	$11,289	$357.73	+$190.97M → GENPF
3	$23,865,535,334	$23,661,184,258.31	$12,123	$472.89	+$23865.52M → GENPF
4	$2,788,853,260,935	$2,763,317,138,127.58	$13,141	$629.86	+$2788853.25M → GENPF
5	$304,771,704,176,462	$301,787,631,187,262.06	$14,408	$846.81	+$304771704.16M → GENPF
6	$31,148,518,911,483,350	$30,822,413,188,014,540.00	$16,021	$1,151.60	+$31148518911.47M → GENPF
7	$2,977,381,874,110,252,500	$2,944,052,958,874,965,500.00	$18,122	$1,588.22	+$2977381874110.23M → GENPF
8	$266,187,755,143,456,800,000	$263,001,956,538,158,780,000.00	$20,930	$2,228.20	+$266187755143456.75M → GENPF
9	$22,259,813,382,715,685,000,000	$21,974,992,484,712,187,000,000.00	$24,792	$3,191.91	+$22259813382715684.00M → GENPF
10	$1,741,245,461,664,930,200,000,000	$1,717,427,461,345,424,000,000,000.00	$30,274	$4,689.40	+$1741245461664930048.00M → GENPF

GENPF vs JNJ: Complete Analysis 2026

GENPF — Stock

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to aid in the restoration of kidney health and kidney function; and Sucanon, an insulin sensitizer that lowers blood sugar by increasing the muscle, fat, and liver's sensitivity to insulin. It also markets and sells nutraceuticals and pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, as well as eye ointments and drops. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

Full GENPF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this GENPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GENPF vs SCHD GENPF vs JEPI GENPF vs O GENPF vs KO GENPF vs MAIN GENPF vs ABBV GENPF vs MRK GENPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.